Abstract: Provided herein are two kinds of toxoid of elastase of Pseudomonas aeruginosa origin, one of which is obtained by treating a purified elastase produced from Pseudomonas aeruginosa with a synthetic peptide for chloroacetyl-N-hydroxy-L-leucyl-L-alanylglycinamide and the other of which is obtained by treating at first with formalin, then, with the synthetic peptide. The present invention also contemplates a method for preparing the toxoids and the use of such toxoids for preventing and treating infections caused by Pseudomonas aeruginosa on human beings and mammalian animals. Acute toxicity of the toxoids is inspected.

Abstract: Toxoids derived from protease and elastase of Pseudomonas aeruginosa which are effective to prevent infections caused by Pseudomonas aeruginosa and production thereof.

Abstract: A three component-mixed vaccine against infections caused by Pseudomonas aeruginosa which comprises as the antigens an infection-protective common antigen OEP (Original Endotoxin Protein) obtained from P. aeruginosa, an elastase toxoid obtained from P. aeruginosa and a protease toxoid obtained from P. aeruginosa.

Abstract: Corneal ulcer, intraperitoneal infectious diseases and serious septicemia diseases caused by infection with P. aeruginosa can be prevented and treated by injection of a .gamma.-globulin aqueous solution containing a large quantity of original endotoxin protein (OEP) antibody, elastase antibody and protease antibody produced against P. aeruginosa.

Abstract: Mink infection caused by Pseudomonas aeruginosa can be prevented by administering to mink a prophylactic preparation in the form of vaccine whose effective component is a compound mainly consisting of protein and a small amount of lipid and sugar derived from Pseudomonas aeruginosa.

Abstract: A therapeutic preparation of a bacterial component (designated as OEP and formally as CWP) derived from Pseudomonas aeruginosa possesses vaccine activity (the effective component being a lipoprotein of Pseudomonas aeruginosa) or the same containing antibiotics is effective in the treatment of mink hemorrhagic pneumonitis and bovine mastitis due to Pseudomonas aeruginosa.

Abstract: This invention relates to a method of preparing original endotoxin protein of Pseudomonas aeruginosa. The invention relates more particularly to a method of preparing original endotoxin protein of Pseudomonas aeruginosa (hereunder abbreviated as OEP) by processing with either proteolytic enzyme or reductant, or further processing with proteolytic enzyme after it has been treated with reductant. The invention also relates to the original endotoxin protein derived from Pseudomonas aeruginosa.

Abstract: The invention involves vaccine preparations comprising cell wall protein component of Pseudomonas aeruginosa as active ingredient and a pharmaceutically acceptable carrier. The preparations are suitable for parenteral administration for prophylactic treatment of disease caused by infection of Pseudomonas aeruginosa. The cell wall protein component is characterized by the fact that the same exhibits low toxicity and without type-specificity to the variety of antigens of Pseudomonas aeruginosa.